Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P08861
UPID:
CEL3B_HUMAN
Alternative names:
Elastase IIIB; Elastase-3B; Protease E
Alternative UPACC:
P08861; B2RE44; P11423; Q5VU28; Q5VU29; Q5VU30
Background:
Chymotrypsin-like elastase family member 3B, also known as Elastase IIIB, Elastase-3B, and Protease E, is recognized for its efficient protease activity with specificity for alanine. Despite its name, it exhibits only minimal elastolytic activity. This protein plays a crucial role in various biological processes through its proteolytic functions.
Therapeutic significance:
Understanding the role of Chymotrypsin-like elastase family member 3B could open doors to potential therapeutic strategies. Its unique protease activity suggests it could be a target for designing specific inhibitors or activators to modulate its function in disease states.